Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. Medtronic has a commercialization deal with the company for the device, which uses a pacing algorithm to actively lower blood pressure in people with pacemakers.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
January has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For example, health tech companies like Medtronic and athenahealth hired new C-suite leaders, and providers like Cleveland Clinic and Jefferson Health announced rounds of job cuts.
A Beverly Hills surgeon has sued Medtronic, alleging that the medical device giant stole her design for a hernia mesh device. One lawyer pointed out that this is not a typical patent infringement case.
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
Abbott and Medtronic — typically regarded as competitors — have recently joined forces. The two companies teamed up to collaborate on a continuous glucose monitoring system that combines Abbott’s FreeStyle Libre technology with Medtronic’s automated insulin delivery system.
Break down the silos. Take control of your provider data.
During a panel discussion on GLP-1s at the Abarca Forward conference, one health executive stressed the importance of a food-as-medicine approach.
Geoff Martha sought to establish a clear line between popular understanding of AI created by apps like ChatGPT and what he believes is the significant impact that Medtronic's AI-enabled products are already having on patients and other healthcare stakeholders today.
Gastroenterologist Dr. Austin Chiang has about a decade of experience as a physician influencer on social media. During a conference in Chicago, he encouraged more providers to share their expertise on social media. By having a presence on these platforms, healthcare professionals demonstrate their commitment to meeting patients where they are, he said.
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
Medical billing is a tedious administrative task, but outsourcing it may be the key to increased revenue. Explore the top medical billing outsourcing companies and the benefits of partnering with one.
Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.
Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic’s medical devices.
Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.
Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.
The innovation platform promises to match entrepreneurs with the resources they need to advance treatments for stroke care but also to help the device maker process all the new ideas it sees.